The company is a spin-out from the Universities of Glasgow and Oxford pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins. The Company will use the funding to establish laboratories in Oxford and Glasgow and expand its team to accelerate its bacteriocin development programme.

ADVISORS & FUNDERS